Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

Presentation Details Statistically Significant and Clinically Relevant Results for SB-509 in Development for Treatment of Diabetic Neuropathy

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of encouraging Phase 1b clinical data from its ZFP Therapeutic(TM) program at the 68th Scientific Sessions of the American Diabetes Association (ADA). As disclosed in an oral presentation entitled, "Evidence of Neuroregeneration Using Vascular Endothelial Growth Factor (VEGF) Zinc Finger Protein Activator (SB-509) in Diabetic Neuropathy: A Chronic Degenerative Polyneuropathy," results of Sangamo's Phase 1b clinical trial (SB-509-401) demonstrated statistically significant improvements in measurements of nerve health and function in subjects with diabetic neuropathy.

"We are excited by the clinically relevant magnitude of improvements that were observed in measurements of nerve health and function in subjects with mild to moderate diabetic neuropathy over the six month trial period after a single administration of SB-509," commented the presenter, Mark Kipnes, M.D., lead investigator on the Phase 1 trial and an endocrinologist at the Diabetes and Glandular Disease Clinic, San Antonio, Texas. "Analgesics and antidepressants designed to control pain symptoms are the only drugs currently approved to treat this condition. In contrast, SB-509 is designed to address the actual nerve damage. These data demonstrate that SB-509 may have a neuroprotective and a neuroregenerative effect."

The data presented at ADA were collected from subjects with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 (SB-509-401). Subjects recei
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... 22, 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... who allegedly developed Type 2 diabetes due to its ... litigation now underway in U.S. District Court, District of ... documents, the litigation will convene its next Status Conference ... directed Lead Counsel for Plaintiffs and Defendants to meet ...
(Date:11/22/2014)... 22, 2014 The Sports Conflict Institute ... Baroff to its team of conflict resolution professionals. Baroff ... coach, and referee. He has over 30 years experience as ... , “I'm very excited to connect with SCI and bring ... interests to a program with a complete sports focus,” says ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... are better when patients are treated in an ambulance by ... German researchers report. The sooner patients get the clot ... outcome after a stroke, the researchers noted. For the best ... hour after stroke symptoms start, the researchers said. "The ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... By Amanda Gardner HealthDay Reporter , MONDAY, ... ubiquitous and pedestrian drugs -- aspirin -- may cut the ... has not yet spread beyond the gland, a new study ... 5,000 men with prostate cancer, 2,000 of whom were taking ...
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... chemotherapy to radiation therapy for muscle invasive bladder cancer allows ... their bladders two years after treatment. This compares to 54 ... largest randomized study of its kind presented at the plenary ... the American Society for Radiation Oncology (ASTRO). , "The trial ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... By Serena Gordon HealthDay Reporter , MONDAY, Oct. ... to sleep-starved parents: Most infants will start sleeping through the ... may take a little longer, however, is for the baby,s ... schedule, according to the study. "The most rapid changes ...
... PICK: Pregnancy outcome affected by immune system genes ... Moffett, at the University of Cambridge, United Kingdom, has ... to and provide protection from common disorders of pregnancy, ... A key step in the initiation of a successful ...
Cached Medicine News:Health News:Aspirin May Help Patients Beat Prostate Cancer 2Health News:Aspirin May Help Patients Beat Prostate Cancer 3Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9
Surgical Drop-Off Apron...
All Day Comfort for the Upper Body...
All Day Comfort for the Upper Body...
Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....
Medicine Products: